Embolism in Medical Technology

CRESTOR(R) Reduced Risk of Blood Clots in the Veins

... (DVT), which occurs in the 'deep veins' usually in the legs or pelvis. An embolism is created if the clot travels through the venous system. Blood clots lodging in the lungs are known as a pulmonary embolism (PE). Estimates suggest that at least 350,000 and as many as 600,000 ...

Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)

... are deep-vein thrombosis (DVT), usually in the leg, and pulmonary embolism (PE). VTE is also a common complication among acutely ill medical ... the prophylaxis of deep vein thrombosis (DVT) which may lead to pulmonary embolism (PE); in patients undergoing abdominal surgery who are at risk for ...

ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402

... leg. DVT is a major public health issue and it is estimated that in the U.S. alone, more than 350,000 individuals are affected by DVT or pulmonary embolism (PE) each year. Moreover, DVT and PE together may be responsible for more than 100,000 deaths in the U.S. each year.(1) It is estimated that ...

Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study

... for a long period of time, such as when recovering from surgery or traveling long distances. The true number of people who develop a pulmonary embolism is unknown, but AHRQ data for hospital patients show that 258,000 individuals were diagnosed with the condition in 2006, and 20,000 died as a result. ...

Beating Blood Clots after Joint Replacement

... receives pre and post-joint replacement, causes controversy. "Patients undergoing total joint replacement are at high risk for DVT and pulmonary embolism (PE), unless they receive some form of prophylaxis ( http://www.aaos.org/about/papers/advistmt/1027.asp )," stated Richard J. Friedman, MD, FRCSC, ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... as compared with idraparinux. Rates of recurrent venous thromboembolism (2.3 percent versus 3.2 percent) and fatal or non-fatal pulmonary embolism (1.6 percent versus 1.8 percent) were similar with both idrabiotaparinux and idraparinux. Levels of Factor Xa activity were identical in ...

APTA Supports Surgeon General's 'Call to Action' to Prevent Deep Vein Thrombosis and Pulmonary Embolism

... the recent "Call to Action" by Acting Surgeon General Steven K Galson, MD, MPH to reduce the number of cases of deep vein thrombosis and pulmonary embolism in the United States. According to Susan Scherer, PT, PhD, associate professor of physical therapy at Regis University in Denver and member of ...

Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women

... and congenital heart disease have been substantially expanded since the previous guideline. Arterial ischemic stroke (AIS), usually caused by embolism or thrombosis, is difficult to diagnose in children because underlying health conditions are markedly different than those in adult stroke and up to ...

Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials

... details of the methodology and purpose of its Phase I Human Trials with its PulmoBind Molecular Imaging technology for the diagnosis of Pulmonary embolism and Pulmonary Hypertension. The work will be carried out by the Pulmo BioTech subsidiary, PulmoScience Inc., and the title of the work is: "Phase I ...

Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein

... suffering from several cardiovascular conditions including Acute Myocardial Infarction, Ischemic Stroke, Peripheral Arterial Disease and Pulmonary embolism in a cost efficient manner," said Nirmal Mulye, Ph.D., founder and President of Nostrum. Nostrum will first pursue the clinical development and ...

Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes

... MD, director of the cardiac catheterization laboratory at Auckland City Hospital, Auckland, New Zealand. "Although there are other mechanisms, distal embolism of atherosclerotic plaque and/or thrombus is recognized to be a frequent cause." The A-F study is being presented today in a Late-Breaking ...

New Deep Vein Thrombosis (DVT) Registry Data Show Clot Quickly Removed, Blood Flow Restored in Large Patient Registry

... (blood thinners), which prevents future clots but does not break up the existing clot. DVT can lead to serious consequences, including pulmonary embolism (PE) or post-thrombotic syndrome (PTS). Approximately 200,000 individuals die annually as a result of pulmonary embolism. The standard initial ...

Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study

... the long-term efficacy and safety of investigational oral direct thrombin inhibitor dabigatran etexilate for the prevention of stroke and systemic embolism in patients with atrial fibrillation. RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) is the largest stroke prevention in atrial ...

The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

... stroke develop Deep-Vein Thrombosis (DVT) and 20% develop Pulmonary embolism (PE). PREVAIL study showed a significant 43% relative risk reduction in ... are deep-vein thrombosis (DVT), usually in the leg, and pulmonary embolism (PE). VTE is also a common complication among individuals who ...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

... significant differences were observed for symptomatic pulmonary embolism (PE) or fatal PE. The statistically significant relative risk reduction of ... are deep-vein thrombosis (DVT), usually in the leg, and pulmonary embolism (PE). VTE is also a common complication among acutely-ill ...

DVT Awareness Survey Findings: Heart and Respiratory Patients

... 2007 /PRNewswire/ -- Up to two million Americans are affected each year by DVT, with up to 600,000 hospitalized. Its primary complication, pulmonary embolism (PE), claims up to 300,000 lives annually -- more than breast cancer and AIDS combined. People who suffer from cardiovascular disease may be at ...

DVT Awareness Survey Findings for Respondents in High-Risk Groups: Obese Individuals

... 2007 /PRNewswire/ -- Up to two million Americans are affected each year by DVT, with up to 600,000 hospitalized. Its primary complication, pulmonary embolism (PE), claims up to 300,000 lives annually -- more than breast cancer and AIDS combined. The Coalition to Prevent Deep-Vein Thrombosis (DVT) ...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

... VENOUS THROMBOSIS AND PULMONARY EMBOLISM. This drug has demonstrated a significantly increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma who were treated with REVLIMID(R) (lenalidomide) combination therapy. Patients and physicians are advised to ...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

... a 49% relative risk reduction (RRR) (p less than 0.001) in the composite primary endpoint of deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE) and all-cause mortality compared to those treated with enoxaparin. A 62% reduction of risk (p=0.01) for developing major VTE (the composite of ...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

... demonstrated a 49% relative risk reduction (RRR) (p<0.001) of the composite primary endpoint of deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE) and all-cause mortality compared to those treated with enoxaparin. An even greater (62%) reduction of risk (p=0.01) of developing major VTE (the ...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

... This may occur in any part of the venous system, but the most common manifestations are deep-vein thrombosis (DVT), usually in the leg, and pulmonary embolism (PE). VTE is a common complication among patients hospitalized for major surgery or with a severe medical illness such as cancer or cardiopulmonary ...